AI Article Synopsis
- Arctic foxes were immunized with a lyophilized SAG2 oral rabies vaccine, and the study assessed its effectiveness through serologic response and survival after rabies exposure.
- Vaccine virus was not detected in the saliva shortly after ingestion, but all vaccinated foxes showed a strong immune response within two weeks and survived for 17 weeks post-challenge.
- The findings indicate that the SAG2 oral rabies vaccine is likely effective in arctic and subarctic areas, where extreme temperatures do not compromise its ability to stimulate immune responses.
Article Abstract
Arctic foxes (Alopex lagopus) were immunized with lyophilized SAG2 oral rabies vaccine. The effectiveness of this vaccine was determined by serologic response and survival to challenge by rabies virus isolated from a red fox from Alaska (USA). No vaccine virus was found in saliva 1-72 hr after ingestion. At 2 wk after vaccination, all foxes had seroconverted, with rabies virus neutralizing antibody levels of 0.2-3.1 IU ml(-1). All vaccinated foxes survived to week 17 after challenge, and hippocampus, pons, and cerebellum were free of rabies virus as determined by direct immunofluorescence testing after death. One of four nonvaccinated foxes survived challenge and was free of rabies virus in neural tissue, and no rabies virus neutralizing antibody was detected in blood. Our results suggest that the lyophilized SAG2 oral rabies vaccine could be effective in arctic and subarctic regions, where freezing air and ground temperatures probably would not reduce its immunogenicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7589/0090-3558-40.2.328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!